The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...
Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Fintel reports that on November 18, 2025, B of A Securities maintained coverage of Werewolf Therapeutics (NasdaqGS:HOWL) with a Buy recommendation. As of November 17, 2025, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results